Home » Drug Information » FDA Approved Drugs » 1996
Medical Areas: Endocrinology | Nephrology | Oncology | Family Medicine | Urology
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Lupron Depot (leuprolide acetate for depot suspension)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Abbott Laboratories
Approval Status: Approved January 1996
Treatment Area: prostate cancer
A three month, 22.5 mg dosage of Lupron Depot was approved as a
treatment for advanced-stage prostate cancer.
In clinical trials, the safety and efficacy of Lupron Depot
(three month, 22.5 mg) were similar to that of the original daily
subcutaneous injection and the monthly depot formulation.
The most common side effect reported was hot flashes (58.5%).
Like other treatment options, it may also cause impotence.
Mechanism of Action
Lupron Depot (three month, 22.5 mg) works by shutting down the
production of the hormone testosterone, which plays a significant
role in the growth of prostate cancer. Decreasing the levels of
testosterone in the body also alleviates the bone pain and urinary
problems that may be associated with metastatic prostate